Shamit Chopra1, Dev P Kamdar2, David S Cohen3, Lance K Heilbrun4, Daryn Smith4, Harold Kim5, Ho-Sheng Lin3, John R Jacobs3, George Yoo3. 1. Department of Head and Neck Surgery, Patel Super Specialty Hospital, Civil Lines, Jalandhar, Punjab, India. 2. Department of Otolaryngology-Head and Neck Surgery, Long Island Jewish School of Medicine, Long Island, New York. 3. Department of Otolaryngology-Head and Neck Surgery, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, U.S.A. 4. Biostatistics Core, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, U.S.A. 5. Department of Radiation Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, U.S.A.
Abstract
OBJECTIVE: To determine the outcome of definitive concurrent chemoradiation with platinum for locally advanced sinonasal carcinomas. STUDY DESIGN: Retrospective cohort. METHODS: Twenty-three nonsurgically and definitively treated patients diagnosed between July 1998 and February 2009 were analyzed. Patients with adenoid cystic carcinoma or adenocarcinoma were treated with photons and neutrons; the other histologies received photons alone. The vast majority received chemotherapy. Descriptive statistics were utilized, and Kaplan-Meier estimates were computed. RESULTS: Female (57%) and Caucasian (74%) preponderance were observed. Eighty-seven percent were unresectable; the maxillary and nasoethmoid sites were equally prevalent. Intensity-modulated radiation therapy (IMRT) and photons alone were utilized in 74% and 70%, respectively. Platinum agents were given in 95% of chemotherapy patients. Complete response was observed in 64% of patients. Median progression-free survival (PFS) and overall survival (OS) were 28.8 and 65.3 months, respectively. Three-year PFS and OS rates were 44% and 72%, respectively; 5-year PFS and OS rates were 30% and 60%, respectively. Intensity-modulated radiation therapy and a maxillary site of origin showed a trend toward superior PFS; higher-dose regimens were associated with somewhat shorter PFS. Relapse was observed in 59% of patients, predominantly local. There were few unanticipated adverse effects, and no grade IV/V events were reported. CONCLUSION: Advanced sinonasal carcinomas are chemoradiosensitive tumors, albeit with a high propensity for local relapse. There is a definite indication for IMRT and a potential curative role of platinum-based chemoradiation regimens. LEVEL OF EVIDENCE: 4. Laryngoscope, 127:855-861, 2017.
OBJECTIVE: To determine the outcome of definitive concurrent chemoradiation with platinum for locally advanced sinonasal carcinomas. STUDY DESIGN: Retrospective cohort. METHODS: Twenty-three nonsurgically and definitively treated patients diagnosed between July 1998 and February 2009 were analyzed. Patients with adenoid cystic carcinoma or adenocarcinoma were treated with photons and neutrons; the other histologies received photons alone. The vast majority received chemotherapy. Descriptive statistics were utilized, and Kaplan-Meier estimates were computed. RESULTS: Female (57%) and Caucasian (74%) preponderance were observed. Eighty-seven percent were unresectable; the maxillary and nasoethmoid sites were equally prevalent. Intensity-modulated radiation therapy (IMRT) and photons alone were utilized in 74% and 70%, respectively. Platinum agents were given in 95% of chemotherapy patients. Complete response was observed in 64% of patients. Median progression-free survival (PFS) and overall survival (OS) were 28.8 and 65.3 months, respectively. Three-year PFS and OS rates were 44% and 72%, respectively; 5-year PFS and OS rates were 30% and 60%, respectively. Intensity-modulated radiation therapy and a maxillary site of origin showed a trend toward superior PFS; higher-dose regimens were associated with somewhat shorter PFS. Relapse was observed in 59% of patients, predominantly local. There were few unanticipated adverse effects, and no grade IV/V events were reported. CONCLUSION: Advanced sinonasal carcinomas are chemoradiosensitive tumors, albeit with a high propensity for local relapse. There is a definite indication for IMRT and a potential curative role of platinum-based chemoradiation regimens. LEVEL OF EVIDENCE: 4. Laryngoscope, 127:855-861, 2017.
Authors: Susanne Ingrid Mayr; Kamber Hafizovic; Frank Waldfahrer; Heinrich Iro; Birgitta Kütting Journal: Int Arch Occup Environ Health Date: 2009-11-03 Impact factor: 3.015
Authors: J N Waldron; B O'Sullivan; P Warde; P Gullane; F F Lui; D Payne; B Cummings Journal: Int J Radiat Oncol Biol Phys Date: 1998-05-01 Impact factor: 7.038
Authors: Bradford S Hoppe; Lauren D Stegman; Michael J Zelefsky; Kenneth E Rosenzweig; Suzanne L Wolden; Snehal G Patel; Jatin P Shah; Dennis H Kraus; Nancy Y Lee Journal: Int J Radiat Oncol Biol Phys Date: 2006-12-08 Impact factor: 7.038
Authors: Piet Dirix; Sandra Nuyts; Yasmyne Geussens; Mark Jorissen; Vincent Vander Poorten; Eric Fossion; Robert Hermans; Walter Van den Bogaert Journal: Int J Radiat Oncol Biol Phys Date: 2007-06-14 Impact factor: 7.038
Authors: Shawn P McKay; Terry Y Shibuya; William B Armstrong; Hau-Sin Wong; Apraham M Panossian; Joel Ager; Robert H Mathog Journal: Am J Otolaryngol Date: 2007 Sep-Oct Impact factor: 1.808
Authors: J D Forman; M Duclos; R Sharma; P Chuba; K Hart; M Yudelev; S Devi; W Court; F Shamsa; P Littrup; D Grignon; A Porter; R Maughan Journal: Int J Radiat Oncol Biol Phys Date: 1996-05-01 Impact factor: 7.038
Authors: Bradford S Hoppe; Carl J Nelson; Daniel R Gomez; Lauren D Stegman; Abraham J Wu; Suzanne L Wolden; David G Pfister; Michael J Zelefsky; Jatin P Shah; Dennis H Kraus; Nancy Y Lee Journal: Int J Radiat Oncol Biol Phys Date: 2008-04-18 Impact factor: 7.038
Authors: Olena Klymenko; Anna Maria Stefanie Buchberger; Barbara Wollenberg; Klaus-Dietrich Wolff; Victoria Kehl; Stephanie E Combs; Anja Pickhard; Steffi U Pigorsch Journal: Cancers (Basel) Date: 2021-05-14 Impact factor: 6.639
Authors: Nathan Y Yu; Mauricio E Gamez; William F Hartsell; Henry K Tsai; George E Laramore; Gary L Larson; Charles B Simone; Carl Rossi; Sanford R Katz; Matthew R Buras; Michael A Golafshar; Carlos E Vargas; Samir H Patel Journal: Adv Radiat Oncol Date: 2019-07-16